SCHREE PETTIGREW: Open Payments
NPI 1255660684 · NEW BEDFORD, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,768 in 261 payments from 18 companies in 2025. Trend: 2023 $3,436 · 2024 $4,477 · 2025 $5,768
Food & beverage: $5,763Education: $5
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 49 | $1,140 |
| Otsuka America Pharmaceutical, Inc. | 40 | $755 |
| ABBVIE INC. | 31 | $536 |
| Teva Pharmaceuticals USA, Inc. | 22 | $455 |
| Alkermes, Inc. | 25 | $453 |
| Indivior Inc. | 17 | $447 |
| Janssen Pharmaceuticals, Inc | 13 | $400 |
| Vanda Pharmaceuticals Inc. | 15 | $389 |
| Neurocrine BioSciences, Inc. | 18 | $370 |
| Axsome Therapeutics, Inc. | 13 | $325 |
Products named: CAPLYTA, REXULTI, VRAYLAR, SUBLOCADE, UZEDY, INVEGA SUSTENNA, ARISTADA, FANAPT.
Industry payments across MA — which companies pay providers there.
